Ricerca avanzata

Herve Hoppenot ricopre la carica di presidente, presidente e amministratore delegato di Incyte Corp. È anche nel consiglio di Biotechnology Innovation Organization, Cellectis SA e Pharmaceutical Research & Manufacturers of America. Nella sua carriera passata è stato presidente di Novartis Oncology, Inc., presidente di Novartis Pharmaceuticals Corp., Head-US Oncology Business Unit di Aventis SA, vicepresidente della divisione oncologia di Aventis Pharmaceuticals, Inc., direttore di Rhone Poulenc AG, Inc. e Head-US Oncology Business Unit di Rhone-Poulenc Rorer Pharmaceuticals, Inc.

Axel Hoppenot worked as an Executive VP-Sales & Marketing at Monte-Carlo Société des Bains de Mer SA from 2004 to 2021.

Mr. David Hoppenot is a Co-Founder & Special Advisor at Atalante SAS where he joined in 2004.
Mr. Hoppenot also served on the board at Adverline SA, Opteven Assurances SA and Utram SA. He received his undergraduate degree from Essca Ecole De Management and a graduate degree from Escp Business School.

Patrice Hoppenot is currently the Chairman at I&P Développement.
He was previously an Independent Director at Sperian Protection SAS in 2010, a Director at Burelle SA from 2005 to 2011, and a Director at Burelle Participations SA.

Patrick Hervy is currently a Director at Catalent Maryland, Inc. He was previously the Chairman, President & Chief Executive Officer at XLHealth Corp.
in 1998.
Mr. Hervy holds an MBA degree from The Wharton School of the University of Pennsylvania.